NRIX
Nurix Therapeutics, Inc.
Latest Form 4:Sale$109KbyHansen Gwenn (Chief Scientific Officer) · filed Aug 5, 2026
Nurix Therapeutics, Inc. (NRIX) has 32 SEC Form 4 filings (91 transaction rows) in the rolling window, disclosed by 3 distinct insiders. Most recent filing: Aug 5, 2026.
The most active filer is Chief Legal Officer Ring Christine with 16 filings. Insiders have net sold $3.1M over the trailing 6 months.
- Industry:Biotechnology
- CEO:Arthur T. Sands
- Employees:314
- HQ:Brisbane, CA, US
- IPO:2020-07-24
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$4.3M
reported sales (SEC code S)
Unique Insiders
3
in the rolling window
Market Cap
$2.7B
latest known value
| Source | ||||||
|---|---|---|---|---|---|---|
| Chief Scientific Officer | Sale | 4,356 | $109K | Aug 5 | SEC ↗ | |
| Chief Scientific Officer | Sale | 4,111 | $100K | Aug 5 | SEC ↗ | |
| Chief Financial Officer | Sale | 4,761 | $116K | Aug 5 | SEC ↗ | |
| Chief Legal Officer | Sale | 16,589 | $382K | Aug 3 | SEC ↗ | |
| Chief Financial Officer | Sale | 2,845 | $67K | Jul 30 | SEC ↗ | |
| Chief Legal Officer | Sale | 3,847 | $90K | Jul 30 | SEC ↗ | |
| Chief Scientific Officer | Sale | 3,847 | $90K | Jul 30 | SEC ↗ | |
| Chief Legal Officer | Sale | 11,008 | $259K | Jul 2 | SEC ↗ | |
| Chief Scientific Officer | Sale | 5,394 | $108K | Jun 25 | SEC ↗ | |
| Chief Legal Officer | Sale | 28,935 | $581K | Jun 25 | SEC ↗ | |
| Chief Legal Officer | Sale | 8,148 | $135K | Jun 2 | SEC ↗ | |
| Chief Financial Officer | Sale | 14,055 | $233K | May 5 | SEC ↗ | |
| Chief Legal Officer | Sale | 8,148 | $138K | May 4 | SEC ↗ | |
| Chief Legal Officer | Sale | 5,394 | $90K | May 1 | SEC ↗ | |
van Houte HansFirst in 3 months | Chief Financial Officer | Sale | 2,388 | $40K | Apr 30 | SEC ↗ |
| Chief Legal Officer | Sale | 3,214 | $53K | Apr 30 | SEC ↗ | |
Hansen GwennFirst in 3 months | Chief Scientific Officer | Sale | 3,214 | $53K | Apr 30 | SEC ↗ |
| Chief Legal Officer | Sale | 8,148 | $124K | Apr 2 | SEC ↗ | |
| Chief Legal Officer | Sale | 8,148 | $126K | Mar 2 | SEC ↗ | |
| Chief Legal Officer | Sale | 14,261 | $238K | Feb 9 | SEC ↗ | |
Hansen GwennFirst in 3 months | Chief Scientific Officer | Sale | 4,895 | $81K | Jan 30 | SEC ↗ |
| Chief Financial Officer | Sale | 3,661 | $61K | Jan 30 | SEC ↗ | |
| Chief Legal Officer | Sale | 4,421 | $73K | Jan 30 | SEC ↗ | |
| Chief Legal Officer | Sale | 3,760 | $69K | Jan 20 | SEC ↗ | |
| Chief Legal Officer | Sale | 3,760 | $67K | Dec 18 | SEC ↗ | |
| Chief Legal Officer | Sale | 37,600 | $642K | Nov 24 | SEC ↗ | |
| Chief Financial Officer | Sale | 6,284 | $79K | Nov 3 | SEC ↗ | |
van Houte HansFirst filing | Chief Financial Officer | Sale | 3,130 | $40K | Oct 30 | SEC ↗ |
Hansen GwennFirst filing | Chief Scientific Officer | Sale | 4,087 | $52K | Oct 30 | SEC ↗ |
Ring ChristineFirst filing | Chief Legal Officer | Sale | 3,644 | $47K | Oct 30 | SEC ↗ |
Related companies
Nurix Therapeutics, Inc. is in the Healthcare sector.